Evidence map›Paper›PMID 33177102›Full record

ArticleAnnals of the rheumatic diseases2022

Response to 'Correspondence on 'Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study'' by Zheng

Dimitrios A Pappas, Gregory St John, Carol J Etzel, Stefano Fiore, Taylor Blachley, Toshio Kimura, Rajeshwari Punekar, Kelechi Emeanuru, Jeannie Choi, Susan Boklage and 1 more

Open access · bronzeAbstract readLetterComment
PubMed Publisher
In one paragraph

Article in Annals of the rheumatic diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 78% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Dimitrios A PappasDivision of Rheumatology, Department of Medicine, Columbia University Medical Center, New York, New York, USA dpappas@corrona.org.ORCID http://orcid.org/0000-0001-8338-027X
Gregory St JohnMedical Affairs, Regeneron Pharmaceuticals, Tarrytown, New York, USA.
Carol J EtzelCorrona, Albany Medical College and The Center for Rheumatology, Waltham, Massachusetts, USA.
Stefano FioreMedical Affairs, Sanofi, Bridgewater, New Jersey, USA.
Taylor BlachleyCorrona, Albany Medical College and The Center for Rheumatology, Waltham, Massachusetts, USA.
Toshio KimuraMedical Analytics, Regeneron Pharmaceuticals, Tarrytown, New York, USA.
Rajeshwari PunekarReal World Evidence Generation, Sanofi Genzyme, Cambridge, Massachusetts, USA.
Kelechi EmeanuruCorrona, Albany Medical College and The Center for Rheumatology, Waltham, Massachusetts, USA.
Jeannie ChoiHealth Economics and Value Assessment, Sanofi, Bridgewater, New Jersey, USA.
Susan BoklageMedical Affairs, Regeneron Pharmaceuticals, Tarrytown, New York, USA.
Joel M KremerCorrona, Albany Medical College and The Center for Rheumatology, Waltham, Massachusetts, USA.
Center for Rheumatology · USRegeneron (United States) · USSanofi (United States) · USColumbia University Irving Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidBiological ProductsHumansNecrosisRegistriesTumor Necrosis Factor InhibitorsAntirheumatic AgentsBiological ProductsTumor Necrosis Factor Inhibitorsarthritishealth careoutcome assessmentpatient reported outcome measuresrheumatoidtumor necrosis factor inhibitors

Identifiers

PMID33177102
OpenAlexW3101208665

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.